AU2687301A - Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes - Google Patents

Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes

Info

Publication number
AU2687301A
AU2687301A AU26873/01A AU2687301A AU2687301A AU 2687301 A AU2687301 A AU 2687301A AU 26873/01 A AU26873/01 A AU 26873/01A AU 2687301 A AU2687301 A AU 2687301A AU 2687301 A AU2687301 A AU 2687301A
Authority
AU
Australia
Prior art keywords
treating diabetes
glycosidase inhibitors
pharmacological uses
novel glycosidase
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26873/01A
Other languages
English (en)
Inventor
Nushin Banu Helene Aghajari
Richard Michel Haser
Xavier Guy Robert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2687301A publication Critical patent/AU2687301A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AU26873/01A 1999-12-23 2000-12-20 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes Abandoned AU2687301A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9916409A FR2802817B1 (fr) 1999-12-23 1999-12-23 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
FR9916409 1999-12-23
PCT/FR2000/003600 WO2001047528A2 (fr) 1999-12-23 2000-12-20 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete

Publications (1)

Publication Number Publication Date
AU2687301A true AU2687301A (en) 2001-07-09

Family

ID=9553772

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26873/01A Abandoned AU2687301A (en) 1999-12-23 2000-12-20 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes

Country Status (7)

Country Link
US (1) US20030143713A1 (enExample)
EP (1) EP1239863A2 (enExample)
JP (1) JP2003518501A (enExample)
AU (1) AU2687301A (enExample)
CA (1) CA2395305A1 (enExample)
FR (1) FR2802817B1 (enExample)
WO (1) WO2001047528A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents
WO2000066175A2 (en) 1999-04-30 2000-11-09 Slil Biomedical Corporation Conjugates as therapies for cancer and prostate diseases
IL146127A0 (en) * 1999-04-30 2002-07-25 Slil Biomedical Corp Conformationally restricted polymine analogs as disease therapies
EP1436246A1 (en) * 2001-10-16 2004-07-14 SLIL Biomedical Corporation Oligoamine compounds and derivatives thereof for cancer therapy
JP2004189714A (ja) * 2002-12-09 2004-07-08 Rasanen Tiina-Liisa すい臓炎の治療と予防ならびに肝臓再生機能の誘導のための薬剤
US7332604B2 (en) 2005-09-20 2008-02-19 Schering Corporation 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8153611B2 (en) * 2007-06-28 2012-04-10 Basf Beauty Care Solutions France S.A.S. Use of sulfated oligosaccharides as slimming cosmetic ingredients
FR2917971B1 (fr) 2007-06-28 2009-10-23 Engelhard Lyon Soc Par Actions Composition amincissante
JP5693953B2 (ja) * 2007-06-28 2015-04-01 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 痩身用組成物
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
US20110065671A1 (en) 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
RU2392933C2 (ru) * 2008-07-18 2010-06-27 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) Средство, обладающее гиполипидемическими свойствами
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
AR073412A1 (es) 2008-10-03 2010-11-03 Schering Corp Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende.
CA2739491A1 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379564A1 (en) 2008-12-19 2011-10-26 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
WO2010071822A1 (en) 2008-12-19 2010-06-24 Schering Corporation Piperidine and piperazine derivatives and methods of use thereof
WO2010075271A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
AU2009330206A1 (en) 2008-12-23 2011-07-07 Merck Sharp & Dohme Corp. Pyrimidine derivatives as GPCR modttlators for use in the treatment of obesity and diabetes
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US20120022057A1 (en) 2009-03-18 2012-01-26 Schering Corporation Bicyclic compounds as inhibitors of diacyglycerol acyltransferase
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
WO2010114957A1 (en) 2009-04-03 2010-10-07 Schering Corporation Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
US8470773B2 (en) 2009-06-12 2013-06-25 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US20120172369A1 (en) 2009-09-14 2012-07-05 Ting Pauline C Inhibitors of diacylglycerol acyltransferase
EP2485735B1 (en) 2009-10-08 2015-07-29 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (fabp)
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
WO2011113060A2 (en) * 2010-03-12 2011-09-15 Trana Discovery, Inc. Antiviral compounds and methods of use thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
ITMI20130555A1 (it) * 2013-04-09 2014-10-10 Giuliani Spa Composizione farmaceutica o cosmetica per contrastare l¿invecchiamento della pelle attraverso un¿azione antiinfiammatoria
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1768934A1 (de) * 1968-07-15 1972-03-16 Bayer Ag Verfahren zur Anreicherung von Polypeptiden,vorzugsweise von Enzymen und Enzym-Inhibitoren
US4228274A (en) * 1976-09-28 1980-10-14 Merck & Co., Inc. 1-Substituted glycopyranosides
DE3123520A1 (de) * 1981-06-13 1982-12-30 Bayer Ag, 5090 Leverkusen Gesaettigte aminocyclitderivate, ihre herstellung undsie enthaltende arzneimittel
US5141739A (en) * 1986-07-03 1992-08-25 Advanced Magnetics, Inc. Delivery of x-ray contrast agents using receptor mediated endocytosis
WO1989008098A2 (en) * 1988-02-19 1989-09-08 The Upjohn Company Lipophilic polyamines useful for treating hypercholesterolemia
US5077313A (en) * 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
DE58903113D1 (de) * 1988-11-25 1993-02-04 Lubec Gert Behandlung von durch glucose ausgeloester quervernetzung von collagen bei diabetes mellitus-patienten durch arginin, spermidin, kreatin oder agmatin.
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
WO1994012464A1 (en) * 1992-12-03 1994-06-09 Charonis Aristidis S Protective role of polyamines in modifications of basement membrane macromolecules
US5744453A (en) * 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
NL1004379C2 (nl) * 1996-10-29 1998-05-08 Borculo Cooep Weiprod Toepassing van suikeraminen en suikeramiden als lijm, alsmede nieuwe suikeraminen en suikeramiden.
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs

Also Published As

Publication number Publication date
FR2802817B1 (fr) 2002-10-11
EP1239863A2 (fr) 2002-09-18
WO2001047528A3 (fr) 2002-06-20
CA2395305A1 (fr) 2001-07-05
JP2003518501A (ja) 2003-06-10
WO2001047528A2 (fr) 2001-07-05
FR2802817A1 (fr) 2001-06-29
US20030143713A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
AU5279100A (en) E1 endoglucanase variants y245g, y82r and w42r
AU2001216582A1 (en) Modified plating solution for plating and planarization and process utilizing same
ZA200203316B (en) New use and novel n-azabicyclo-amide derivatives.
AU3862600A (en) Multifonctional laminate structure and process
AU763094C (en) Benzimidazoles, production thereof and use thereof as medicaments
MXPA03005713A (es) Derivados de tetrahidropiridina, su preparacion y su uso como inhibidores de proliferacion celular.
AU5170900A (en) Cell proliferation inhibitors
AU6136499A (en) Injector, methods for using injector, and kit
AU7550398A (en) Heterocyclic compounds, their production and use
AU6901200A (en) Form keys and method using form keys
AU1812001A (en) Cotton transcription factors and their uses
AUPP995799A0 (en) Improvements in hinges
AU3301700A (en) (n)-sulfonyl-dipeptide derivatives, production and use thereof in therapy
AU5838700A (en) Method for treating and preventing finger disorders
AU4579500A (en) Small electronic articles for personal use
AU6635800A (en) Pyridomorphinans, thienomoprhinans and use thereof
AU1703301A (en) Block copolymers and method for the production and utilization thereof
IL136950A0 (en) Heterocyclic compounds, their production and use
AU7123400A (en) Method for reducing costs associated with inebriation
GB9917593D0 (en) Compound, composition, process and use
AU1907901A (en) Sandwich construction and method for its manufacture
AU1792901A (en) Methods for treating and preventing diabetic complications
AU3968500A (en) Arrangement and method to improve information security
AUPP807799A0 (en) Polynucleotide and method
AU6006800A (en) Treating cells

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase